GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose
Launched by UPPSALA UNIVERSITY · Mar 2, 2010
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Effects of GIP and GLP-1 on gastric emptying, appetite control and insulin release in relation to glucose levels in the bloodstream. Infusions of GIP and GLP-1 are given under simultaneous gastric emptying study and appetite questionnaires and blood sampling for analysis of insulin, glucose, and other gut hormones such as glucagon, ghrelin, and PYY, as well as those administered, GIP and GLP-1.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women
- • 18-50 years old;
- • otherwise healthy and HIV and HCB, HCV negative
- Exclusion Criteria:
- • Age \>50,
- • all types of diseases and drug users.
About Uppsala University
Uppsala University, a prestigious institution located in Sweden, is renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive expertise in various fields of health sciences to conduct innovative studies aimed at improving patient outcomes and understanding complex diseases. With a strong emphasis on ethical standards and rigorous scientific methodologies, Uppsala University collaborates with a network of researchers, healthcare professionals, and industry partners to facilitate groundbreaking clinical trials that contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
Per M Hellstrom, MD, PhD
Principal Investigator
Karolinska Institutet, Uppsala University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials